Geert Vanhooren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/870238/publications.pdf

Version: 2024-02-01

57 papers

31,629 citations

32 h-index 55 g-index

58 all docs 58 docs citations

58 times ranked 23348 citing authors

#	Article	IF	Citations
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1139-1151.	13.9	9,839
2	Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. New England Journal of Medicine, 2008, 359, 1317-1329.	13.9	5,749
3	Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet, The, 2007, 369, 275-282.	6.3	2,527
4	Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 806-817.	13.9	2,207
5	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	6.3	1,871
6	Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2008, 358, 2127-2137.	13.9	1,142
7	Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet, The, 2010, 375, 985-997.	6.3	1,135
8	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, The, 2008, 372, 1174-1183.	6.3	896
9	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine, 2008, 359, 1238-1251.	13.9	882
10	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	13.9	841
11	Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. New England Journal of Medicine, 2013, 368, 1083-1091.	13.9	781
12	Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine, 2008, 359, 1225-1237.	13.9	703
13	The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet, The, 2011, 377, 741-750.	6.3	485
14	Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials. Stroke, 2008, 39, 3316-3322.	1.0	397
15	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology. The. 2008. 7. 875-884.	4.9	310
16	B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 855-865.	4.9	264
17	Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet, The, 2011, 377, 2013-2022.	6.3	185
18	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurology, The, 2012, 11, 225-231.	4.9	164

#	Article	IF	CITATIONS
19	Granulocyte Colony–Stimulating Factor in Patients With Acute Ischemic Stroke. Stroke, 2013, 44, 2681-2687.	1.0	125
20	Benign paroxysmal positional vertigo of the horizontal canal Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 68-71.	0.9	115
21	Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2013, 173, 1682-92.	2.6	100
22	Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology, 2021, 96, e2824-e2838.	1.5	95
23	Partial Aortic Occlusion for Cerebral Perfusion Augmentation. Stroke, 2011, 42, 1680-1690.	1.0	94
24	Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurology, The, 2012, 11, 512-520.	4.9	70
25	Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study, Cerebrovascular Diseases, 2009, 27, 509-518.	0.8	64
26	Status Update and Interim Results from the Asymptomatic Carotid Surgery Trial-2 (ACST-2). European Journal of Vascular and Endovascular Surgery, 2013, 46, 510-518.	0.8	61
27	Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurology, The, 2013, 12, 866-872.	4.9	56
28	Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. European Stroke Journal, 2019, 4, 254-262.	2.7	48
29	Recommendations on telestroke in Europe. European Stroke Journal, 2019, 4, 101-109.	2.7	42
30	Intravenous thrombolysis in stroke mimics: results from the <scp>SITS</scp> International Stroke Thrombolysis Register. European Journal of Neurology, 2019, 26, 1091-1097.	1.7	41
31	Modified Rankin scale as a determinant of direct medical costs after stroke. International Journal of Stroke, 2017, 12, 392-400.	2.9	40
32	VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444). International Journal of Stroke, 2007, 2, 144-150.	2.9	38
33	Hypothermia for Stroke: Call to Action 2010. International Journal of Stroke, 2010, 5, 489-492.	2.9	29
34	Nuclear oculomotor nerve paralysis. Neuro-Ophthalmology, 1987, 7, 219-222.	0.4	25
35	Stroke coach: a pilot study of a personal digital coaching program for patients after ischemic stroke. Acta Neurologica Belgica, 2020, 120, 91-97.	0.5	21
36	The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic stroke. Health and Quality of Life Outcomes, 2019, 17, 31.	1.0	20

#	Article	IF	Citations
37	Polyneuropathy in lithium intoxication. Muscle and Nerve, 1990, 13, 204-208.	1.0	19
38	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. Stroke, 2015, 46, 2779-2785.	1.0	19
39	Angiotensin Receptor Blockade in Acute Stroke. the Scandinavian Candesartan Acute Stroke Trial: Rationale, Methods and Design of a Multicentre, Randomised- and Placebo-Controlled Clinical Trial (NCT00120003). International Journal of Stroke, 2010, 5, 423-427.	2.9	17
40	Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial: TableÂ1. Journal of NeuroInterventional Surgery, 2013, 5, i21-i24.	2.0	17
41	Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature. Transplant International, 2011, 24, e30-e34.	0.8	15
42	The impact of COVID-19 on acute stroke care in Belgium. Acta Neurologica Belgica, 2021, 121, 1251-1258.	0.5	15
43	The relationship between Home-time, quality of life and costs after ischemic stroke: the impact of the need for mobility aids, home and car modifications on Home-time. Disability and Rehabilitation, 2020, 42, 419-425.	0.9	11
44	Crossed innervation of the superior rectus. Clinical Neurology and Neurosurgery, 1992, 94, 73.	0.6	10
45	An individualized coaching program for patients with acute ischemic stroke: Feasibility study. Clinical Neurology and Neurosurgery, 2017, 154, 89-93.	0.6	9
46	Cerebral Venous Thrombosis and the G20210A Mutation of Factor II. Stroke, 2000, 31, 543-548.	1.0	8
47	ARE ACE-INHIBITORS OR ARB'S STILL NEEDED FOR CARDIOVASCULAR PREVENTION IN HIGH RISK PATIENTS? INSIGHTS FROM PROFESS AND TRANSCEND. Acta Clinica Belgica, 2010, 65, 107-114.	0.5	4
48	Reversion of cerebral artery stenoses due to tuberculomas with TNF- \hat{l}_{\pm} antibodies. Clinical Neurology and Neurosurgery, 2012, 114, 1016-1018.	0.6	4
49	Multicenter, retrospective analysis of endovascular treatment for acute ischemic stroke in nonagenarians. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104817.	0.7	4
50	Letters to the editor. Muscle and Nerve, 1991, 14, 574-578.	1.0	3
51	LESSONS FROM ONTARGET. Acta Clinica Belgica, 2008, 63, 142-151.	0.5	3
52	Value of treatment by comprehensive stroke services for the reduction of critical gaps in acute stroke care in Europe. European Journal of Neurology, 2021, 28, 717-725.	1.7	3
53	Thrombectomy is a cost-saving procedure up to 24Âh after onset. Acta Neurologica Belgica, 2022, 122, 163-171.	0.5	3
54	The SITS Open Study. Stroke, 2021, 52, 792-801.	1.0	2

#	Article	IF	CITATIONS
55	Tuberothalamic infarction causing a central Horner syndrome with contralateral ataxia and paraphasia. Acta Neurologica Belgica, 2015, 115, 727-729.	0.5	1
56	Temperature threshold in amyotrophic lateral sclerosis (ALS). Clinical Neurology and Neurosurgery, 1989, 91, 368-369.	0.6	0
57	Reply to Vanhooren on "crossed innervation of the superior rectus― Clinical Neurology and Neurosurgery, 1992, 94, 74.	0.6	0